Nordion
Nordion is a Canadian health-science company supplying cobalt-60 and radiation-sterilization technologies for medical, industrial, and consumer applications.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Nordion is a Canadian health-science business whose principal activities have centered on medical isotopes, cobalt-60, and gamma-irradiation systems. Its products support two closely related markets: the sterilization of medical and other manufactured products, and the use of radiation in the treatment of disease. The company is headquartered in Ottawa, Ontario, and has also operated or maintained facilities and offices serving international customers, including a site in Abingdon, Oxfordshire, a sales office in Hong Kong, and research and demonstration capabilities in Laval, Quebec. The business originated in 1946 as the radium sales department of Eldorado Mining and Refining Ltd. During its early development, the division worked on radiotherapy equipment using cobalt-60, a radioactive isotope whose gamma emissions can be used to destroy cancerous tissue. Its role expanded when it became responsible for commercializing radioisotopes produced at the Chalk River Nuclear Laboratories in Ontario. In 1951, Eldorado organized this activity as its Commercial Products Division, with cobalt-60 for cancer treatment becoming a major focus. Following the creation of Atomic Energy of Canada Limited in 1952, the commercial isotope operation was transferred to that Crown corporation and later became known as its radio-chemical division. In 1988, ownership moved from AECL to the Canadian Development Investment Corporation. The business adopted the name Nordion International Inc. and was sold to MDS Health Group in 1991, becoming associated with the MDS Nordion identity for much of its subsequent development. MDS undertook a strategic repositioning in 2010, divesting MDS Analytical Technologies and MDS Pharma Services. Shareholders approved changing the parent company's name from MDS Inc. to Nordion Inc., and the legal name change took effect on November 1, 2010. Nordion subsequently narrowed its portfolio further. In July 2013, it sold its Targeted Therapies business to BTG plc, leaving sterilization technologies and medical isotopes as its central activities. Nordion's cobalt-60 is used to generate gamma radiation for sterilizing surgical supplies, medical devices, and selected consumer products such as food and cosmetics. The company also designs and sells irradiation systems, including production irradiators, allowing customers to apply gamma processing at industrial scale. In healthcare, cobalt-60 supports radiotherapy applications including stereotactic radiosurgery. The medical-isotopes business historically also supplied isotopes used in medical imaging and radiopharmaceutical production. Sotera Health acquired Nordion in 2014 for US$805 million, according to the cited historical reference. The transaction was presented as creating a vertically integrated sterilization company by combining Nordion's isotope and irradiation capabilities with Sotera Health's broader sterilization activities. Nordion later sold its Medical Isotopes business in 2018, leaving its post-sale profile more concentrated around cobalt-60 supply and gamma-sterilization technologies. The available reference material identifies Riaz Bandali as president but does not provide a complete current executive roster.
History
Nordion traces its origins to 1946, when it operated as the radium sales department of Eldorado Mining and Refining Ltd. The early organization participated in the development of radiotherapy equipment based on cobalt-60, an isotope capable of producing penetrating gamma radiation. This work connected the business to both cancer treatment and the emerging commercial use of radioisotopes. The division soon assumed responsibility for selling radioisotopes produced by the Chalk River Nuclear Laboratories in Ontario. In 1951, Eldorado formalized the activity as its Commercial Products Division. The division's work increasingly focused on the commercial handling and distribution of isotopes, particularly cobalt-60 used in radiotherapy. A major institutional change came in 1952, when the Canadian government established Atomic Energy of Canada Limited, or AECL. The Commercial Products Division was transferred to AECL and became its radio-chemical division. Under this structure, the business continued to develop commercial isotope applications while remaining connected to Canada's nuclear research and production infrastructure. In 1988, ownership of the radio-chemical division moved from AECL to the Canadian Development Investment Corporation. The operation adopted the name Nordion International Inc. and was subsequently sold to MDS Health Group in 1991. Under MDS ownership, the business became widely associated with the MDS Nordion name and expanded its role in medical isotopes, radiotherapy-related products, and sterilization technologies. MDS changed its strategic direction in 2010. It disposed of MDS Analytical Technologies and MDS Pharma Services and sought a corporate identity more closely aligned with the remaining business. Shareholders approved the name change from MDS Inc. to Nordion Inc., which became effective on November 1, 2010. The renamed company retained activities in medical isotopes and radiation-based sterilization. In July 2013, Nordion sold its Targeted Therapies business to BTG plc. This divestiture reduced the scope of the portfolio and left the company focused on two principal areas: sterilization technologies and medical isotopes. Its cobalt-60 products supplied the radiation source for gamma sterilization of medical and surgical products, devices, and selected consumer goods, while its irradiation equipment enabled customers to operate commercial processing facilities. Cobalt-60 also remained relevant to cancer-treatment applications such as stereotactic radiosurgery. Sotera Health acquired Nordion in 2014 for US$805 million. The acquisition was framed as a vertical integration of isotope supply and sterilization services and technologies. Nordion's historical business therefore became part of a larger healthcare-services group rather than continuing as an independent listed company. The company later sold its Medical Isotopes business in 2018. This transaction marked another narrowing of Nordion's activities, with the remaining business centered primarily on cobalt-60 and gamma-sterilization technologies. The cited reference describes Ottawa as the corporate headquarters and principal base for cobalt-60 sources, irradiation equipment, and historically produced medical isotopes. Nordion has also been associated with a Gamma Centre of Excellence in Laval, operated with the University of Quebec's Armand Frappier Institute, and an Asia-Pacific sales office in Hong Kong. The available material does not establish a complete chronology of facility openings, leadership changes, or post-2018 operating results.
- 2018
Medical Isotopes business sold
[1]Nordion divests its Medical Isotopes business and becomes more concentrated on cobalt-60 and sterilization technologies.
- 2014
Acquired by Sotera Health
[1]Sotera Health completes the acquisition of Nordion for US$805 million.
- 2013
Targeted Therapies divested
[1]Nordion sells its Targeted Therapies business to BTG plc and concentrates on sterilization technologies and medical isotopes.
- 2010
Corporate name changed to Nordion Inc.
[1]After a strategic repositioning and portfolio divestitures, MDS shareholders approve changing the company name to Nordion Inc.; the change takes effect on November 1.
- 1991
Nordion sold to MDS Health Group
[1]MDS Health Group acquires the Nordion International business.
- 1988
Ownership transferred to CDIC
[1]The radio-chemical division is transferred from AECL to the Canadian Development Investment Corporation and later adopts the Nordion International name.
- 1952
Radioisotope operation transferred to AECL
[1]The commercial products operation moves to Atomic Energy of Canada Limited and becomes its radio-chemical division.
- 1951
Commercial Products Division established
[1]Eldorado creates a dedicated division to manage commercial radioisotope activities, especially cobalt-60 used in cancer treatment.
- 1946
Business begins as Eldorado's radium sales department
[1]The predecessor of Nordion is established within Eldorado Mining and Refining Ltd., with early work connected to radium sales and cobalt-60 radiotherapy development.
Products and positioning
A specialized health-science and radiation-technology supplier positioned at the intersection of medical-device sterilization, industrial irradiation, radiotherapy, and isotope production.
Radioisotope
Cobalt-60
Nordion supplies cobalt-60, a radioactive isotope that emits gamma radiation. Customers use its sources to sterilize medical devices and surgical supplies, process selected food and cosmetic products, and support certain radiotherapy applications, including stereotactic radiosurgery.
Radiation sterilization
Gamma sterilization technologies
These technologies use cobalt-60 gamma radiation to reduce or eliminate harmful microorganisms on manufactured products. The principal applications described for Nordion include medical and surgical supplies, healthcare devices, and selected consumer products.
Industrial irradiation equipment
Production irradiators
Nordion designs and sells irradiators for customers that need production-scale radiation processing. The systems are intended to support commercial gamma-irradiation operations rather than being limited to laboratory demonstration or research use.
Medical isotope supply
Medical isotopes
Medical isotopes were a historical Nordion business used in medical imaging and radiopharmaceutical applications. Nordion sold this business in 2018, so it should be treated as a former rather than a current core offering.
Brand decisions
2018
Sale of Medical Isotopes businessM&ABackground
The business portfolio included both medical isotopes and sterilization technologies.
Action taken
Nordion sold its Medical Isotopes business.
Aftermath
The company became more focused on cobalt-60 supply and gamma-sterilization technologies.
2014
Acquisition by Sotera HealthM&ABackground
Nordion's isotope and irradiation capabilities were strategically relevant to sterilization services.
Action taken
Sotera Health acquired Nordion for US$805 million.
Aftermath
Nordion became part of Sotera Health and was presented as contributing to a vertically integrated sterilization company.
Acquisition value. US$805 million transaction value (2014 acquisition)
2013
Sale of Targeted Therapies businessM&ABackground
Nordion narrowed its portfolio after its broader MDS-era restructuring.
Action taken
The Targeted Therapies business was sold to BTG plc in July 2013.
Aftermath
Nordion focused on sterilization technologies and medical isotopes.
2010
Repositioning around NordionStrategyBackground
MDS pursued a strategic repositioning that included the divestiture of MDS Analytical Technologies and MDS Pharma Services.
Action taken
Shareholders approved changing the corporate name from MDS Inc. to Nordion Inc., with the new name becoming effective on November 1, 2010.
Aftermath
The renamed company presented itself around its remaining isotope and radiation-technology activities.
Recent events
- 2018
Nordion sells Medical Isotopes business[1]
M&A
Nordion divested its Medical Isotopes business, further concentrating the company on cobalt-60 supply and sterilization technologies.
- 2014
Nordion acquired by Sotera Health[1]
M&A
Sotera Health acquired Nordion for US$805 million. The transaction was described as combining Nordion's isotope and irradiation capabilities with sterilization operations to form a vertically integrated sterilization business.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/nordion · Editorial policy · How profiles are compiled